Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China

PURPOSE: The five-year update data from the KEYNOTE-407 study have unveiled noteworthy improvements in survival outcomes achieved with pembrolizumab plus chemotherapy (Pembro+Chemo) compared to placebo plus chemotherapy (Placebo+Chemo) for patients with previously untreated metastatic squamous non-s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xin, Zhang, Huixian, Li, Lan-Fang, Feng, Lei, Liu, Qiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505025/
https://www.ncbi.nlm.nih.gov/pubmed/37719688
http://dx.doi.org/10.2147/RMHP.S429394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505025/
https://www.ncbi.nlm.nih.gov/pubmed/37719688
http://dx.doi.org/10.2147/RMHP.S429394

Ejemplares similares